These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 10899499

  • 1. Coexistent hemoconcentration and hypoosmolality during superovulation and in severe ovarian hyperstimulation syndrome: a volume homeostasis paradox.
    Evbuomwan IO, Davison JM, Murdoch AP.
    Fertil Steril; 2000 Jul; 74(1):67-72. PubMed ID: 10899499
    [Abstract] [Full Text] [Related]

  • 2. Altered osmotic thresholds for arginine vasopressin secretion and thirst during superovulation and in the ovarian hyperstimulation syndrome (OHSS): relevance to the pathophysiology of OHSS.
    Evbuomwan IO, Davison JM, Baylis PH, Murdoch AP.
    Fertil Steril; 2001 May; 75(5):933-41. PubMed ID: 11334905
    [Abstract] [Full Text] [Related]

  • 3. Serum leptin concentrations in patients with severe ovarian hyperstimulation syndrome during in vitro fertilization-embryo transfer treatment.
    Ayustawati, Shibahara H, Hirano Y, Suzuki T, Takamizawa S, Suzuki M.
    Fertil Steril; 2004 Sep; 82(3):579-85. PubMed ID: 15374699
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH.
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [Abstract] [Full Text] [Related]

  • 7. Severe ovarian hyperstimulation syndrome modifies early maternal serum beta-human chorionic gonadotropin kinetics, but obstetrical and neonatal outcomes are not impacted.
    Choux C, Barberet J, Ginod P, Cottenet J, Bruno C, Benzénine E, Sagot P, Fauque P.
    Fertil Steril; 2017 Oct; 108(4):650-658.e2. PubMed ID: 28911926
    [Abstract] [Full Text] [Related]

  • 8. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, Papanikolaou EG, Andersen CY.
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [Abstract] [Full Text] [Related]

  • 9. Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries.
    Agrawal R, Conway G, Sladkevicius P, Tan SL, Engmann L, Payne N, Bekir J, Campbell S, Jacobs H.
    Fertil Steril; 1998 Oct; 70(4):651-8. PubMed ID: 9797093
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Serum vascular endothelial growth factor levels are poorly predictive of subsequent ovarian hyperstimulation syndrome in highly responsive women undergoing assisted conception.
    Mathur R, Hayman G, Bansal A, Jenkins J.
    Fertil Steril; 2002 Dec; 78(6):1154-8. PubMed ID: 12477503
    [Abstract] [Full Text] [Related]

  • 12. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor.
    Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohí J, Simón C.
    Fertil Steril; 1999 Mar; 71(3):482-9. PubMed ID: 10065786
    [Abstract] [Full Text] [Related]

  • 13. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization.
    Enskog A, Henriksson M, Unander M, Nilsson L, Brännström M.
    Fertil Steril; 1999 May; 71(5):808-14. PubMed ID: 10231037
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M, Bogstad J, Bryndorf T, Løssl K, Roskær J, Holland T, Prætorius L, Zedeler A, Nilas L, Pinborg A.
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome.
    Lainas GT, Lainas TG, Venetis CA, Sfontouris IA, Zorzovilis IZ, Alexopoulou E, Tarlatzis BC, Kolibianakis EM.
    Ultrasound Obstet Gynecol; 2018 Jan; 51(1):126-133. PubMed ID: 29105961
    [Abstract] [Full Text] [Related]

  • 18. In-vitro fertilization and the ovarian hyperstimulation syndrome.
    MacDougall MJ, Tan SL, Jacobs HS.
    Hum Reprod; 1992 May; 7(5):597-600. PubMed ID: 1639974
    [Abstract] [Full Text] [Related]

  • 19. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C.
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.